<DOC>
	<DOC>NCT03075878</DOC>
	<brief_summary>This study is being conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and effects on warm autoimmune hemolytic anemia (WAIHA) disease activity markers of intravenous (IV) SYNT001.</brief_summary>
	<brief_title>A Safety Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Anemia, Hemolytic</mesh_term>
	<mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
	<criteria>Subjects must meet the following criteria to be included: Willing and able to read, understand and sign an informed consent form Confirmed diagnosis by enrolling physician of WAIHA Must use medically acceptable contraception Subjects meeting any of the following criteria are to be excluded: Subject unable or unwilling to comply with the protocol Active nonhematologic malignancy or history of nonhematologic malignancy in the 3 years prior to screening (exclusive of nonmelanoma skin cancer and cervical cancer in situ) Positive for HIV or hepatitis C antibody Positive for hepatitis B surface antigen Any exposure to an investigational drug or device within the 30 days prior to screening IVIG treatment within 60 days of screening Plasmapheresis or immunoadsorption within 60 days of screening Subject has any current medical condition that, in the opinion of the Investigator, may compromise their safety or compliance, preclude successful conduct of the study, or interfere with interpretation of the results</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>